498 related articles for article (PubMed ID: 25124891)
21. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
22. Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
Dockery F; Bulpitt CJ; Agarwal S; Rajkumar C
Aging Male; 2002 Dec; 5(4):216-22. PubMed ID: 12630068
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.
Bekelman JE; Mitra N; Handorf EA; Uzzo RG; Hahn SA; Polsky D; Armstrong K
J Clin Oncol; 2015 Mar; 33(7):716-22. PubMed ID: 25559808
[TBL] [Abstract][Full Text] [Related]
24. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.
Cooperberg MR; Hinotsu S; Namiki M; Carroll PR; Akaza H
BJU Int; 2016 Jan; 117(1):102-9. PubMed ID: 25238114
[TBL] [Abstract][Full Text] [Related]
25. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
26. Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk.
Braunstein LZ; Chen MH; Dosoretz DE; Salenius SA; Katin MJ; Nanda A; D'Amico AV
Clin Genitourin Cancer; 2015 Dec; 13(6):555-61. PubMed ID: 26003267
[TBL] [Abstract][Full Text] [Related]
27. Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death.
Pickles T; Tyldesley S; Hamm J; Virani SA; Morris WJ; Keyes M
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):45-52. PubMed ID: 29029889
[TBL] [Abstract][Full Text] [Related]
28. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation.
Wallis CJ; Mahar AL; Satkunasivam R; Herschorn S; Kodama RT; Lee Y; Kulkarni GS; Narod SA; Nam RK
Urology; 2016 Nov; 97():145-152. PubMed ID: 27502032
[TBL] [Abstract][Full Text] [Related]
30. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
Lage MJ; Barber BL; Markus RA
Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy.
D'Alesio V; Salvig BE; Fourakre TN
Consult Pharm; 2011 Jan; 26(1):43-7. PubMed ID: 21224198
[TBL] [Abstract][Full Text] [Related]
32. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
[TBL] [Abstract][Full Text] [Related]
34. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
[TBL] [Abstract][Full Text] [Related]
35. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
36. Factors impacting all-cause mortality in prostate cancer brachytherapy patients with or without androgen deprivation therapy.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE
Brachytherapy; 2010; 9(1):42-9. PubMed ID: 19875340
[TBL] [Abstract][Full Text] [Related]
37. Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population.
Teoh JY; Chan SY; Chiu PK; Poon DM; Cheung HY; Hou SS; Ng CF
BJU Int; 2015 Sep; 116(3):382-7. PubMed ID: 25327618
[TBL] [Abstract][Full Text] [Related]
38. Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
Deka R; Rose BS; Bryant AK; Sarkar RR; Nalawade V; McKay R; Murphy JD; Simpson DR
Cancer; 2019 Apr; 125(7):1070-1080. PubMed ID: 30748008
[TBL] [Abstract][Full Text] [Related]
39. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
40. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]